FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376134712> ?p ?o ?g. }

• W4376134712 endingPage "16" @default.
• W4376134712 startingPage "16" @default.
• W4376134712 abstract "Background: Frailty in non-transplant eligible (NTE) newly diagnosed multiple myeloma (NDMM) patients is associated with toxicity which can negatively affect physical functioning and quality of life (QoL). Older patients may prefer QoL and physical independence over length of life, highlighting the importance of taking health-related (HR) QoL assessment into account for treatment guidance. Methods: The HOVON123 study (NTR4244) was a phase II trial in which 238 NTE-NDMM patients ≥75 years were treated with 9 dose-adjusted cycles MPV. Nine (3 functional; 6 symptom) subscales of two HRQoL instruments (EORTC QLQ-C30 and MY20) were obtained at baseline (T0), after 3 (T1) and 9 (T2) cycles of therapy, and 6 (T3) and 12 (T4) months after discontinuation of therapy in patients without progression. The presence of “tingling hands/feet” was used as a proxy for neuropathy. Differences in baseline HRQoL were analysed with independent t-tests and changes over time with linear mixed models. HRQoL changes and/or differences were reported only when both statistically significant (p<0.005, adjusted for multiple testing) and clinically relevant (>MID). Results: A total of 137 frail and 71 intermediate-fit patients were included in the HRQoL analysis, after exclusion of fit patients and patients whose frailty status or baseline HRQoL questionnaire was missing. Compliance was not materially different in both groups. Frail patients had an inferior HRQoL at baseline in the subscales global health status, physical functioning, fatigue and pain, compared with intermediate-fit patients. Both groups reported improvements in global health status and future perspective. In contrast to intermediate fit patients, frail patients improved in physical functioning, fatigue and pain over time. The improvements in global health status were reached earlier in frail patients (T1) compared with intermediate fit patients (T2), Figure 1. In both intermediate fit and frail patients there was an increase in neuropathy. All other subscales remained within MID ranges and/or were not statistically significant different from baseline. The improvement in global health status sustained after treatment completion (T3-T4) both for frail and intermediate fit patients. This also accounted for future perspective at T3, however, at T4 for intermediate fit patients only. In contrast, the improvement in all other HRQoL domains during treatment, lost clinical relevance and/or statistical significant difference during the TFI. The deterioration in neuropathy remained until T4 in frail patients, but not for intermediate fit patients, reversing at T4, Figure 1. Conclusion: HRQoL in frail patients is inferior as compared to intermediate fit patients at diagnosis. Importantly, treatment improved HRQoL, irrespective of frailty level, being more pronounced and occurring even faster in frail patients. Therefore, physicians should not withhold therapy in these patients because of their frailty status only." @default.
• W4376134712 created "2023-05-12" @default.
• W4376134712 creator A5002972322 @default.
• W4376134712 creator A5004217461 @default.
• W4376134712 creator A5004225429 @default.
• W4376134712 creator A5004736861 @default.
• W4376134712 creator A5006603816 @default.
• W4376134712 creator A5009303586 @default.
• W4376134712 creator A5016822168 @default.
• W4376134712 creator A5020320519 @default.
• W4376134712 creator A5025134911 @default.
• W4376134712 creator A5026709248 @default.
• W4376134712 creator A5027058055 @default.
• W4376134712 creator A5032272072 @default.
• W4376134712 creator A5032546995 @default.
• W4376134712 creator A5032547644 @default.
• W4376134712 creator A5032770450 @default.
• W4376134712 creator A5033564775 @default.
• W4376134712 creator A5038613871 @default.
• W4376134712 creator A5039341334 @default.
• W4376134712 creator A5041505026 @default.
• W4376134712 creator A5046141160 @default.
• W4376134712 creator A5047262318 @default.
• W4376134712 creator A5047666215 @default.
• W4376134712 creator A5055967040 @default.
• W4376134712 creator A5058747587 @default.
• W4376134712 creator A5067870786 @default.
• W4376134712 creator A5070900615 @default.
• W4376134712 creator A5071153255 @default.
• W4376134712 creator A5071204393 @default.
• W4376134712 creator A5075003920 @default.
• W4376134712 creator A5075610619 @default.
• W4376134712 creator A5076539292 @default.
• W4376134712 creator A5078879946 @default.
• W4376134712 creator A5083385949 @default.
• W4376134712 date "2023-05-01" @default.
• W4376134712 modified "2023-10-13" @default.
• W4376134712 title "P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)" @default.
• W4376134712 doi "https://doi.org/10.1097/01.hs9.0000936176.74423.76" @default.
• W4376134712 hasPublicationYear "2023" @default.
• W4376134712 type Work @default.
• W4376134712 citedByCount "0" @default.
• W4376134712 crossrefType "journal-article" @default.
• W4376134712 hasAuthorship W4376134712A5002972322 @default.
• W4376134712 hasAuthorship W4376134712A5004217461 @default.
• W4376134712 hasAuthorship W4376134712A5004225429 @default.
• W4376134712 hasAuthorship W4376134712A5004736861 @default.
• W4376134712 hasAuthorship W4376134712A5006603816 @default.
• W4376134712 hasAuthorship W4376134712A5009303586 @default.
• W4376134712 hasAuthorship W4376134712A5016822168 @default.
• W4376134712 hasAuthorship W4376134712A5020320519 @default.
• W4376134712 hasAuthorship W4376134712A5025134911 @default.
• W4376134712 hasAuthorship W4376134712A5026709248 @default.
• W4376134712 hasAuthorship W4376134712A5027058055 @default.
• W4376134712 hasAuthorship W4376134712A5032272072 @default.
• W4376134712 hasAuthorship W4376134712A5032546995 @default.
• W4376134712 hasAuthorship W4376134712A5032547644 @default.
• W4376134712 hasAuthorship W4376134712A5032770450 @default.
• W4376134712 hasAuthorship W4376134712A5033564775 @default.
• W4376134712 hasAuthorship W4376134712A5038613871 @default.
• W4376134712 hasAuthorship W4376134712A5039341334 @default.
• W4376134712 hasAuthorship W4376134712A5041505026 @default.
• W4376134712 hasAuthorship W4376134712A5046141160 @default.
• W4376134712 hasAuthorship W4376134712A5047262318 @default.
• W4376134712 hasAuthorship W4376134712A5047666215 @default.
• W4376134712 hasAuthorship W4376134712A5055967040 @default.
• W4376134712 hasAuthorship W4376134712A5058747587 @default.
• W4376134712 hasAuthorship W4376134712A5067870786 @default.
• W4376134712 hasAuthorship W4376134712A5070900615 @default.
• W4376134712 hasAuthorship W4376134712A5071153255 @default.
• W4376134712 hasAuthorship W4376134712A5071204393 @default.
• W4376134712 hasAuthorship W4376134712A5075003920 @default.
• W4376134712 hasAuthorship W4376134712A5075610619 @default.
• W4376134712 hasAuthorship W4376134712A5076539292 @default.
• W4376134712 hasAuthorship W4376134712A5078879946 @default.
• W4376134712 hasAuthorship W4376134712A5083385949 @default.
• W4376134712 hasBestOaLocation W43761347121 @default.
• W4376134712 hasConcept C126322002 @default.
• W4376134712 hasConcept C159110408 @default.
• W4376134712 hasConcept C1862650 @default.
• W4376134712 hasConcept C2776364478 @default.
• W4376134712 hasConcept C2778715236 @default.
• W4376134712 hasConcept C2779951463 @default.
• W4376134712 hasConcept C71924100 @default.
• W4376134712 hasConceptScore W4376134712C126322002 @default.
• W4376134712 hasConceptScore W4376134712C159110408 @default.
• W4376134712 hasConceptScore W4376134712C1862650 @default.
• W4376134712 hasConceptScore W4376134712C2776364478 @default.
• W4376134712 hasConceptScore W4376134712C2778715236 @default.
• W4376134712 hasConceptScore W4376134712C2779951463 @default.
• W4376134712 hasConceptScore W4376134712C71924100 @default.
• W4376134712 hasIssue "S2" @default.
• W4376134712 hasLocation W43761347121 @default.
• W4376134712 hasLocation W43761347122 @default.
• W4376134712 hasLocation W43761347123 @default.
• W4376134712 hasOpenAccess W4376134712 @default.
• W4376134712 hasPrimaryLocation W43761347121 @default.
• W4376134712 hasRelatedWork W1993687961 @default.

• next